Logo       Developing the Next Generation of Therapeutics

Home |       About |        Technology |       News |       Investors |       Contact |

 

Mission and Vision

NovoDux is developing the next generation of novel therapeutics to address diseases caused by abnormal angiogenesis, and infectious pathogens. Our proprietary molecules target human proteins involved in abnormal vascular growth, cancer, tumor growth, metastasis, ocular pathologies, diseases of the brain and proteins from infectious pathogens including viruses and bacteria.

The technology comprises multitargeted compounds containing several different stereoisomer peptides with enhanced physicochemical properties making them ideal drug candidates against several target areas including oncology, ocular pathologies, infectious diseases and neurology. We are developing novel and unique therapeutic compounds that specifically and simultaneously target several abnormal proteins involved in these diseases.

NovoDux technology is based on small chiral peptides capable of modifying disease state cell characteristics. The peptides directly impact on the cell by targeting and disrupting the molecular interactions of overexpressed or down regulated proteins that cause disease. NovoDux is building value through its owned intellectual property portfolio of issued patents.

 

Our Name

The name NovoDux, derived from Latin, means 'innovator' and ‘leader'. These attributes reflect our leadership developing the next generation of innovative therapeutics for several human diseases.